NCT04949269View on ClinicalTrials.gov

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

January 3, 2022

Study Completion Date

January 3, 2022

Conditions
Healthy Participants
Interventions
DRUG

Deucravacitinib

Specified dose on specified days

DRUG

Famotidine

Specified dose on specified days

Trial Locations (2)

33126

Quotient Sciences Miami, Miami

78744

PPD Development, LP, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04949269 - A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants | Biotech Hunter | Biotech Hunter